(f) whether M/s. Glaxo has overcharged the consumer on these drugs and formulations and as per the directive of the Delhi High Court, the Company had to deposit the overcharged amount;

(g) if so, what is the total amount charged, the amount assessed and the total amount recovered upto 31st January, 1990; and

(h) what was the liability shown by M/s. Glaxo in their balance sheets for the last three years?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADA SWAMY) : (a) to (c) The prices of Betamethasone bulk drug and its salts were revised on 2nd January, 1989. The revised and pre-revised prices are given below:

Sl. No.	Name of the bulk Drug	Rs./Gms	
		Revised Prices	Pre-revised Prices
1	Betamethasone Alcohol	144·19	113·34
2	Betamethasone Valerate	136·58	105·85
3	Betamethasone Di-Sodium Phosphate	144·58	126·23

The details of formulation prices fixed/notified under DPCO, 1987, including the formulations involved in the court case are given in the Annexed Orders dated 29-8-89 and 7-11-89 [*See* Appendix CLIII, Annexure No. 29].

(d) The increase in formulaion prices was mainly due to increase in the bulk drug prices.

(e) No recommendation from BICP has been received for revision of bulk drug prices under DPCO, 1987.

(f) and (g) In the background of the Delhi High Court's judgement in M/s. Glaxo's case, the recoverable amount from the company is being finalised. The amount received from the company (M/s. Glaxo Limited) upto the 28th February, 1990 is Rs. 819.00 lacs

(h) The company has provided a sum of Rs. 25.63 crores in their accounts up to the end of 1988-89.

Identification of Category I Drugs

705. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what was the decision of Government as contained in the measures regarding Category I drugs;

(b) whether the decision has been implemented in toto by his Ministry;

(c) what are the drugs required for National Health Programme which have not been included in Category-I; and

(d) what steps have been taken to fix responsibility for non-compliance of the Cabinet decision?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M.S. GURUPADASWAMY): (a) and (b) According to the measures announced by the Government in December, 1986, the Category-I would consist of drugs required for the National Health Programme and MAPE (Maximum Allowable Post Manufacturing Expenses) (incurred from the stage of manufacturing to retailing and manufacturers margin) allowed for such drugs would be 75%.

(c) and (d) The Category-I list under Drugs (Prices Control) Order, 1987 is based on the list given by Ministry of Health and Family Welfare which was subsequently reviewed by the Kelkar Committee while considering the representations against inclusion of drugs under price control. In its supplementary report, the Kelkar Committee made recommendations in respect of 5 drugs out of 26 given by the Ministry of Health and Family Welfare, which was then accepted by the Government.

Prices of Formulations

706. SHRI SYED SIBTEY RAZI : Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 1923 given in the Rajya Sabha on the 13th March, 1989 and state:

(a) What were the prices of each pack and strength of Valium, Eskazine, Serenace and Diazepam before the announcement of DPCO, 1987 and what is the present price of each;

(b) what is the percentage change in each case;

(c) whether the monitoring cell of his Ministry has examined the break-up submitted by each company; and

(d) if so, what are the details of examination of cost data and what is the MAPE enjoyed by ex-factory cost on each product by each producer?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY) : (a) to (d) To the extent information is available, the position is given below:

Sl. No.	Product	Price before DPCO, 1987	Price after DPCO, 1987	Percentage increase
		(in Rs.)	(in Rs.)	
1	(i) Valium (Diazepam) 2 mg 10 mg	2·18	2·27	4·12
	(ii) Valium (Diazepam) 5mg	3·18	3·85	21·06
	(iii) Do. 10 mg	5·30	5·52	4·15
	(iv) Do. 10 mg . . . . . 6x2ml Amps.	13·32	13·32	Nil
2	(i) Serenace 0·5 mg 10 tabs.	3·04	3·34	9·87
	(ii) Serenace 1·5 mg 10 tabs.	9·64	10·66	10·58
	(iii) Serenace 5 mg 10 tabs.	21·59	23·74	9·96
	(iv) Serenace 10 mg 10 tabs.	30·32	33·32	9·89
	(v) Serenace 20 mg 10 tabs.	36·20	39·80	9·94